A meta-analysis of 22 RCTs involving 138,282 participants reaffirmed that while most GLP-1 RAs showed no statistically significant prophylactic effect across the neurodegenerative spectrum, semaglutide was notably effective in reducing Parkinson’s incidence in subgroup analyses [129]. This evidence concerns the gene GLP1R and Parkinson disease.